In today’s 340B environment, conversations about manufacturer-requested data often turn on a simple assumption: that the requested data is the same information covered entities already
In today’s 340B environment, how you communicate your program matters just as much as how you manage it. Organizations are increasingly expected to demonstrate not
Virtue 340B helps covered entities and pharmacy leaders move from reactive, vendor-dependent compliance to disciplined, transparent 340B program oversight. Build a compliant, defensible 340B program
The definition of a “patient” has long been a foundational element of 340B compliance, but that foundation is now being challenged. In AbbVie v. HHS,
There is a growing narrative that growth in the 340B program reflects misuse, abuse, or drift from its original intent. That narrative is gaining traction
At GCA340B, staying ahead of the compliance curve isn’t just a priority—it’s the promise we make to every Covered Entity we serve. Compliance and auditing are
Most 340B exposure comes from gradual operational drift, not bad intent. Virtue helps organizations detect and prevent it early. We help hospital leadership understand exposure,
A recent federal court ruling has vacated HRSA’s long-standing 2013 GPO policy, raising new questions about how 340B hospitals can approach initial drug inventory purchases.
A recent court ruling is reshaping how hospitals should approach 340B eligibility—particularly for off-site locations. For years, many have assumed that registration in OPAIS was
In early March 2026, a federal district court issued a significant ruling in Albany Med Health System v. HRSA, challenging long-standing assumptions about when hospital child
